Tags

Type your tag names separated by a space and hit enter

Dry powder inhalable formulations for anti-tubercular therapy.
Adv Drug Deliv Rev. 2016 07 01; 102:83-101.AD

Abstract

Tuberculosis (TB) is an intracellular infectious disease caused by the airborne bacterium, Mycobacterium tuberculosis. Despite considerable research efforts, the treatment of TB continues to be a great challenge in part due to the requirement of prolonged therapy with multiple high-dose drugs and associated side effects. The delivery of pharmacological agents directly to the respiratory system, following the natural route of infection, represents a logical therapeutic approach for treatment or vaccination against TB. Pulmonary delivery is non-invasive, avoids first-pass metabolism in the liver and enables targeting of therapeutic agents to the infection site. Inhaled delivery also potentially reduces the dose requirement and the accompanying side effects. Dry powder is a stable formulation of drug that can be stored without refrigeration compared to liquids and suspensions. The dry powder inhalers are easy to use and suitable for high-dose formulations. This review focuses on the current innovations of inhalable dry powder formulations of drug and vaccine delivery for TB, including the powder production method, preclinical and clinical evaluations of inhaled dry powder over the last decade. Finally, the risks associated with pulmonary therapy are addressed. A novel dry powder formulation with high percentages of respirable particles coupled with a cost effective inhaler device is an appealing platform for TB drug delivery.

Authors+Show Affiliations

Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia.Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia.Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Jordan, Amman 1192, Jordan.Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia.Tuberculosis Research Program, Centenary Institute, The University of Sydney, NSW 2006, Australia; Infectious Diseases and Immunology, Sydney Medical School, The University of Sydney, NSW 2006, Australia.Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia. Electronic address: kim.chan@sydney.edu.au.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27212477

Citation

Parumasivam, Thaigarajan, et al. "Dry Powder Inhalable Formulations for Anti-tubercular Therapy." Advanced Drug Delivery Reviews, vol. 102, 2016, pp. 83-101.
Parumasivam T, Chang RY, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83-101.
Parumasivam, T., Chang, R. Y., Abdelghany, S., Ye, T. T., Britton, W. J., & Chan, H. K. (2016). Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews, 102, 83-101. https://doi.org/10.1016/j.addr.2016.05.011
Parumasivam T, et al. Dry Powder Inhalable Formulations for Anti-tubercular Therapy. Adv Drug Deliv Rev. 2016 07 1;102:83-101. PubMed PMID: 27212477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dry powder inhalable formulations for anti-tubercular therapy. AU - Parumasivam,Thaigarajan, AU - Chang,Rachel Yoon Kyung, AU - Abdelghany,Sharif, AU - Ye,Tian Tian, AU - Britton,Warwick John, AU - Chan,Hak-Kim, Y1 - 2016/05/17/ PY - 2015/12/11/received PY - 2016/05/13/revised PY - 2016/05/14/accepted PY - 2016/5/24/entrez PY - 2016/5/24/pubmed PY - 2017/12/19/medline KW - Antibiotics KW - Dry powder inhaler KW - Inhaled risks KW - Particle engineering KW - Pulmonary formulations KW - Tuberculosis KW - Vaccines SP - 83 EP - 101 JF - Advanced drug delivery reviews JO - Adv. Drug Deliv. Rev. VL - 102 N2 - Tuberculosis (TB) is an intracellular infectious disease caused by the airborne bacterium, Mycobacterium tuberculosis. Despite considerable research efforts, the treatment of TB continues to be a great challenge in part due to the requirement of prolonged therapy with multiple high-dose drugs and associated side effects. The delivery of pharmacological agents directly to the respiratory system, following the natural route of infection, represents a logical therapeutic approach for treatment or vaccination against TB. Pulmonary delivery is non-invasive, avoids first-pass metabolism in the liver and enables targeting of therapeutic agents to the infection site. Inhaled delivery also potentially reduces the dose requirement and the accompanying side effects. Dry powder is a stable formulation of drug that can be stored without refrigeration compared to liquids and suspensions. The dry powder inhalers are easy to use and suitable for high-dose formulations. This review focuses on the current innovations of inhalable dry powder formulations of drug and vaccine delivery for TB, including the powder production method, preclinical and clinical evaluations of inhaled dry powder over the last decade. Finally, the risks associated with pulmonary therapy are addressed. A novel dry powder formulation with high percentages of respirable particles coupled with a cost effective inhaler device is an appealing platform for TB drug delivery. SN - 1872-8294 UR - https://www.unboundmedicine.com/medline/citation/27212477/Dry_powder_inhalable_formulations_for_anti_tubercular_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-409X(16)30153-3 DB - PRIME DP - Unbound Medicine ER -